Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions

Annals of Internal Medicine

Volumn 131, Issue 2, 1999, Pages 81-87

  Lucas, Gregory M ^a,b   Chaisson, Richard E ^a,b   Moore, Richard D ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; INDINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; VIRUS RNA;

ADULT; ALLERGIC REACTION; ARTICLE; DRUG ABUSE; ETHNIC GROUP; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NEPHROLITHIASIS; OUTPATIENT DEPARTMENT; PARESTHESIA; PRIORITY JOURNAL; RISK FACTOR; TASTE DISORDER; TREATMENT FAILURE; URBAN AREA; VIRUS LOAD;

EID: 0033587510     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-131-2-199907200-00002     Document Type: Article

References (31)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853-60.
2. Detels R, Munoz A, McFarlane G, Kingsley LA, Margolick JB, Giorgi J, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. AIDS Cohort Study Investigators. JAMA. 1998;280:1497-503.
3. Flexner C. HIV-protease inhibitors. N Engl J Med. 1998;338:1281-92.
4. Deeks SG, Smith M, Holodniy M, Kahn JO. HIV-1 protease inhibitors. A review for clinicians. JAMA. 1997;277:145-53.
5. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997;337:725-33.
6. Saag M, Gersten M, Chang Y. Long term virological and immunological effect of the HIV protease inhibitor Viracept (nelfinavir mesylate) in combination with zidovudine (AZT) and lamivudine (3TC) [Abstract], In: Program and Abstracts of the Infectious Disease Society of America 35th Annual Meeting, San Francisco, 13-16 September 1997:112.
7. Kahn J, Mayers D, Riddler S, Stein D, Bach M, Havlir D, et al. Durable clinical anti-HIV-1 activity (60 weeks) and tolerability for efavirenz (DMP 266) in combination with indinavir (IDV) suppression to "less than 1copy/ml" (OD= background) by Amplicor as a predictor of virologic treatment response [DMP 266-003, cohort IV] [Abstract]. 5th Conf Retrovir Oppor Infect. 1998;Feb 1-5:208.
8. Vanhove GF, Schapiro JM, Winters MA, Merigan TC, Blaschke TF. Patient compliance and drug failure in protease inhibitor monotherapy [Letter]. JAMA. 1996;276:1955-6.
9. + T cell changes in patients failing potent protease inhibitor therapy [Abstract]. 5th Conf Retrovir Oppor Infect. 1998;Feb 1-5:419.
10. Rothenberg R, Woerfel M, Stonebumer R, Milberg J, Parker R, Truman B. Survival with the acquired immunodeficiency syndrome. Experience with 5833 cases in New York City. N Engl J Med. 1987;317:1297-302.
11. Friedland GH, Sartzman B, Vileno J. Freeman K, Schrager LK, Klein RS. Survival differences in patients with AIDS. J Acquir Immune Defic Syndr. 1991; 4:144-53.
12. Hogg RS, Strathdee SA, Craib KJ, O'Shaughnessy MV, Montaner JS, Schechter MT. Lower socioeconomic status and shorter survival following HIV infection. Lancet. 1994;344:1120-4.
13. invirase (saquinavir mesylate) capsules product monograph [package insert]. Nutley, NJ: Roche Laboratories; 1997.
14. Levine AM, Richardson JL, Marks G, Chan K, Graham J, Selser JN, et al. Compliance with oral drug therapy in patients with hematologic malignancy. J Clin Oncol. 1987;5:1469-76.
15. Wood PR, Casey R, Kolski GB, McCormick MC. Compliance with oral theophylline therapy in asthmatic children. Ann Allergy. 1985;54:400-4.
16. Turner J, Wright E, Mendella L, Anthonisen N. Predictors of patient adherence to long-term home nebulizer therapy for COPD. The IPPB Study Group. Intermittent Positive Pressure Breathing. Chest. 1995;108:394-400.
17. Eldred LJ, Wu AW, Chaisson RE, Moore RD. Adherence to antiretroviral therapy and pneumocystis prophylaxis in HIV disease. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18:117-25.
18. Mocroft A, Gill MJ, Davidson W, Phillips AN. Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor. AIDS. 1998;12:2161-7.
19. Chaisson RE, Keruly JC, Moore RD. Race, sex, drug use and progression of human immunodeficiency virus disease. N Engl J Med. 1995;333:751-6.
20. Kissinger P, Cohen D, Brandon W, Rice J, Morse A, Clark R. Compliance with public sector HIV medical care. J Natl Med Assoc. 1995;87:19-24.
21. Danner SA, Carr A, Leonard JM, Lehman LM, Gudiol F, Gonzales J, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. N Engl J Med. 1995;333:1528-33.
22. Clumeck N, Colebunders B, Vandercam B, Kabeya K, Cassano P, Sommereijns B, et al. Randomized comparative outcome trial of indinavir (I) and ritonavir (R) in protease inhibitors (Pl) naïve patients (p) with CD4 below 100 cells/microliter [Abstract]. 5th Conf Retrovir Oppor Infect. 1998;Feb 1-5:386.
23. Moore RD, Fortgang I, Keruly J, Chaisson RE. Adverse events from drug therapy for human immunodeficiency virus disease. Am J Med. 1996;101:34-40.
24. Drusano GL. Bilello JA, Stein DS, Nessly M, Meibohm A, Emini EA, et al. Factors influencing the emergence of resistance to indinavir: role of virologic, immunologic, and pharmacologic variables. J Infect Dis. 1998;178: 360-7.
25. Kaufmann D, Pantaleo G, Sudre P, Telenti A. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study [Letter]. Lancet. 1998;351:723-4.
26. Coombs RW, Welles SL, Hooper WC, Reichelderfer PS, D'Aquila RT, Japour AJ, et al. Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. AIDS Clinical Trials Group (ACTG) 116B/117 Study Team. ACTG Virology Committee Resistance and HIV-1 RNA Working Groups. J Infect Dis. 1996; 174:704-12.
27. Marschner IC, Collier AC, Coombs RW, D'Aquila RT, DeGruttola V, Fischl MA, et al. Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. J Infect Dis. 1998;177:40-7.
28. Hughes MD, Johnson VA, Hirsch MS, Bremer JW, Elbeik T, Erice A, et al. Monitoring plasma HIV-I RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team. Ann Intern Med. 1997;126:929-38.
29. O'Brien WA, Hartigan PM, Martin D, Esinhart J, Hill A, Benoit S, et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. N Engl J Med. 1996;334:426-31.
30. Hecht FM, Grant RM, Petropoulos CJ, Dillon B, Chesney MA, Hellmann NS, et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcnptase and protease inhibitors. N Engl J Med. 1998;339:307-11.
31. Cohen OJ, Fauci AS. Transmission of multidrug-resistant human immunodeficiency virus - the wake-up call [Editorial]. N Engl J Med. 1998;339:341-3.